Aster DM Quality Care Ltd
ASTERDMAster DM Quality Care Ltd's price has outrun its earnings. +20.7% in a year against EPS −93.0% — the market is paying now for delivery later.
The sharpest disagreement: profits are rising, but only 20% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch.
The price is in a confirmed uptrend (27 weeks in) while the P/E sits at the 100th percentile of its own 8-year range. Underneath, the last four quarters read improving — profit −69.1% year on year, and 20% of the last 3 years' profit arrived as cash. What settles it: whether the cash starts following the profit.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Aster DM Quality Care Ltd trades at ₹763, in a confirmed uptrend and 27 weeks into that stage. That is +5.8% against its own 200-day average. It sits at 66% of a 52-week range of ₹555 to ₹870. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 1 straight week.
Today the stock is in a confirmed uptrend — week 27 of stage 2, confirmed. At ₹763 it trades +5.8% versus its 200-day average and sits at 66% of its 52-week range (₹555–₹870).
Against the market, two honest reads. Cumulative: over the last 8.5 years the stock moved +342% while the NIFTY 500 moved +156% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 1 straight week — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Aster DM Quality Care Ltd trades at 184.0× P/E, about the priciest it has ever traded. Its long-run median P/E is 41.2×, measured across 8.1 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 184.0× is about the priciest it has ever traded, against a long-run median of 41.2× measured over 8.1 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
🚨 Why the multiple sits where it does: over the past year annual EPS moved −93.0% against a +20.7% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 5y, of the +27.4%/yr price move, ~+4.8%/yr came from earnings growth and ~+22.6 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Improving Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Aster DM Quality Care Ltd reads as improving on its fundamental arc. Improving — profit growth bottomed 3 quarters ago at −93.3% and has held its recovery at +3.7%, ROCE holding at 10.8%. The read is built from 12 quarters across 4 curves, on full evidence.
Why it matters: a sustained climb off the trough is the setup this page is built to catch — the question moves to what you pay for it.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +12.2% | +15.7% | −11.6% | −1.2% |
| Profit | −92.1% | −3.5% | +19.1% | +48.8% |
| EPS | −93.0% | −4.2% | +20.4% | +43.7% |
| Share price | +20.7% | +30.8% | +27.4% | — |
4-Factor Sector Score
34.3/100 — rank 16 of 19 in Hospitals · 100% evidence confidence
Aster DM Quality Care Ltd scores 34.3 out of 100 against the 19 companies it is compared with in Hospitals, ranking 16. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 15.7 + 9 + 1.2 + 8.4 = 34.3. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Aster DM Quality Care Ltd reported ₹1,311 Cr of revenue in the Jun 26 quarter, +21.6% year on year. That is the 10th straight quarter of year-on-year growth. Over 10 years it has compounded at −1.2% a year. The last full year, FY26, came in at ₹4,643 Cr. The last four reported quarters add to ₹4,876 Cr.
FY26 revenue came in at ₹4,643 Cr (+12.2% on the year), capping 10 years at −1.2% compound. The latest quarter (Jun 26) printed ₹1,311 Cr, +21.6% year on year — the 10th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +15.8% growth against the decade's −1.2% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +15.7% over the last 4 quarters against +12.4%/yr over the last 8 — accelerating; TTM profit +3.7% vs −73.9%/yr — accelerating.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Aster DM Quality Care Ltd's operating margin is 20.0% in the Jun 26 quarter, +1.0 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 13 fiscal years the operating margin has ranged 6.0% to 19.0%.
The latest quarter's operating margin is 20.0%, +1.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 6.0%–19.0%, and FY26's 19.0% is the top of that band — a record year.
Why the margin moved: operating margin went +0.8 pp year on year while gross margin went +0.7 pp — the gain came mostly from the gross line: input costs and pricing.
Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Aster DM Quality Care Ltd earned ₹29.0 Cr of net profit in the Jun 26 quarter, −69.1% year on year. Full-year FY26 profit was ₹427 Cr. The 10-year compound rate is 48.8%. That is 2.2% of the quarter's revenue. The same quarter a year earlier earned ₹94.0 Cr. 2 of the last 12 reported quarters were loss-making.
Jun 26 profit was ₹29.0 Cr, −69.1% year on year. On the full year, FY26 printed ₹427 Cr (−92.1%), and the 10-year compound rate is 48.8%.
🚨 Why profit moved: revenue contributed +21.6% and the margin +1.0 pp — the quarter was revenue-led, with the margin roughly flat.
Pace comparison, last four quarters: profit +4.1% vs revenue +15.8%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 20% of Aster DM Quality Care Ltd's reported profit arrived as operating cash — a gap worth watching. In FY26 that was ₹656 Cr of operating cash against ₹427 Cr of profit. After ₹713 Cr of capital spending, ₹−57.0 Cr was left as free cash.
FY26: operating cash of ₹656 Cr against reported profit of ₹427 Cr, leaving free cash of ₹−57.0 Cr after ₹713 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 20% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
🚨 Why conversion sits at 20%: the cash cycle tightened 29 days between FY21 and FY26 — cash that used to wait in the cycle now reaches the bank sooner. Less than 70% of profit arriving as cash is the thing to watch on this page.
Router verdict: no single sink dominates — the next section checks both the working-capital cycle and the capital spending.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Aster DM Quality Care Ltd's cash conversion cycle runs −112 days in FY26, down from −83 days in FY21. Capital spending ran ₹−3,936 Cr over the last 3 years. At FY26 sales of ₹4,643 Cr each day of that cycle holds about ₹12.7 Cr, so roughly ₹−1,425 Cr sits inside the business at any moment.
FY26: debtors at 24 days, inventory at 32 days — roughly 1.1 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of −112 days, tighter than FY21's −83.
The full loop: cash goes out to suppliers and production on day 0; stock waits 32 days to sell; customers pay about 24 days after that; and suppliers themselves are paid at 168 days — netting out to the −112-day cycle.
In money terms: at FY26 sales of ₹4,643 Cr, each day of the cycle holds about ₹12.7 Cr — so the −112-day loop keeps roughly ₹−1,425 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹−3,936 Cr over the last 3 fiscal years against ₹733 Cr of depreciation — spending at or below maintenance level. Capital work-in-progress stands at ₹420 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: neither the cycle nor the build-out is hoarding the cash — the machine is reasonably clean.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Aster DM Quality Care Ltd earns a ROCE of 12% in FY26. That is up from a trough of 1% in FY17. Return on invested capital clears the cost of that capital by −3.5 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 9.2% net margin on 0.57× asset turns.
FY26 ROCE is 12%, recovered from a FY17 trough of 1% — the full ladder below shows the fall and the climb, undoctored.
🚨 Why the return is what it is — the wiring (FY26): 9.2% net margin × 0.57× asset turns × 1.92× balance-sheet leverage ≈ 10.1% on equity. Margin does its share; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 8.5% − 12.0% = a −3.5 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Aster DM Quality Care Ltd carries total debt of ₹2,220 Cr against shareholder equity of ₹4,834 Cr as of Mar 26, a debt-to-equity of 0.46. On the annual view that ratio went from 1.10 in FY22 to 0.46 in FY26. Read the returns elsewhere on this page with that leverage in mind.
Mar 26: total debt of ₹2,220 Cr against shareholder equity of ₹4,834 Cr — a debt-to-equity of 0.46. On the annual view, debt-to-equity went from 1.10 (FY22) to 0.46 (FY26). Read the returns on this page with that leverage in mind.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Foreign institutions cut 13.5 points of Aster DM Quality Care Ltd over 8 quarters, the biggest move on the register. That takes foreign institutions to 10.3% of the company. Promoters moved +11.8 points over the same window, to 53.7%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Foreign institutions: −13.5 points over 8 quarters to 10.3%; Promoters: +11.8 points over 8 quarters to 53.7%; Domestic institutions: −4.4 points over 8 quarters to 16.5%.
🚨 Why the register moved: foreign institutions drove it (−13.5 points), absorbed on the other side by promoters (+11.8 points) — distribution into the market’s bid.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Aster DM Quality Care Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1KMC Speciality Hospitals (India) Ltd524520 | 78.8/100Favorable setup82% evidence | LEADER | 32.5/35 Revenue 35.1% · PAT 100% · OPM change 6 pp 95% evidence | 20.6/25 ROCE 26.2% · OPM 31% 76% evidence | 11.2/20 P/E 40.5× · PEG — 50% evidence | 14.5/20 RS sector 31.1% · RS bench 48% · 1Y 103.9%12 of 12 weeks ahead 100% evidence |
| Exact sum: 32.5 + 20.6 + 11.2 + 14.5 = 78.8 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Artemis Medicare Services LtdARTEMISMED | 72.8/100Favorable setup100% evidence | LEADER | 26.7/35 Revenue 15% · PAT 29.9% · OPM change 4 pp 100% evidence | 13.3/25 ROCE 14.6% · OPM 20% 100% evidence | 13.8/20 P/E 47.1× · PEG 1.09 100% evidence | 19.0/20 RS sector 17.3% · RS bench 33.5% · 1Y 51.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 26.7 + 13.3 + 13.8 + 19 = 72.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Sakar Healthcare LtdSAKAR | 68.6/100Favorable setup87% evidence | LEADER | 31.9/35 Revenue 43.9% · PAT 71.4% · OPM change 5 pp 95% evidence | 10.8/25 ROCE 12.4% · OPM 29% 95% evidence | 6.5/20 P/E 71.4× · PEG — 50% evidence | 19.4/20 RS sector 77.4% · RS bench 98.9% · 1Y 248.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 31.9 + 10.8 + 6.5 + 19.4 = 68.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Apollo Hospitals Enterprise LtdAPOLLOHOSP | 62.9/100Mixed-positive evidence82% evidence | LEADER | 23.8/35 Revenue 17.2% · PAT 33.2% · OPM change 1 pp 95% evidence | 14.8/25 ROCE 17.4% · OPM 16% 76% evidence | 12.8/20 P/E 60.4× · PEG — 50% evidence | 11.5/20 RS sector -0.4% · RS bench 13.5% · 1Y 13.2%8 of 12 weeks ahead 100% evidence |
| Exact sum: 23.8 + 14.8 + 12.8 + 11.5 = 62.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Dr Agarwals Eye Hospital LtdDRAGARWQ | 61.4/100Mixed-positive evidence94% evidence | BREAKING OUT | 22.2/35 Revenue 20.1% · PAT 31.6% · OPM change -2 pp 100% evidence | 17.9/25 ROCE 17.4% · OPM 30% 100% evidence | 11.9/20 P/E 33.6× · PEG 1.41 100% evidence | 9.4/20 RS sector -4% · RS bench 6.3% · 1Y 17.9%2 of 9 weeks ahead 70% evidence |
| Exact sum: 22.2 + 17.9 + 11.9 + 9.4 = 61.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Kovai Medical Center & Hospital LtdKOVAI | 57.7/100Mixed-positive evidence100% evidence | BREAKING OUT | 19.7/35 Revenue 15% · PAT 15.8% · OPM change 1 pp 100% evidence | 18.6/25 ROCE 22.6% · OPM 29% 100% evidence | 9.9/20 P/E 26.5× · PEG 1.7 100% evidence | 9.5/20 RS sector -4.9% · RS bench 8.6% · 1Y 0.9%9 of 12 weeks ahead 100% evidence |
| Exact sum: 19.7 + 18.6 + 9.9 + 9.5 = 57.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Rainbow Childrens Medicare LtdRAINBOW | 55.5/100Mixed-positive evidence100% evidence | LEADER | 18.3/35 Revenue 18.3% · PAT 12.4% · OPM change 0 pp 100% evidence | 17.6/25 ROCE 17.4% · OPM 29% 100% evidence | 8.2/20 P/E 51.2× · PEG 2.97 100% evidence | 11.4/20 RS sector -3.5% · RS bench 10% · 1Y -4.3%10 of 12 weeks ahead 100% evidence |
| Exact sum: 18.3 + 17.6 + 8.2 + 11.4 = 55.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Global Health LtdMEDANTA | 55.4/100Mixed-positive evidence100% evidence | LEADER | 11.8/35 Revenue 21.3% · PAT 3.4% · OPM change -2 pp 100% evidence | 15.2/25 ROCE 17.4% · OPM 22% 100% evidence | 10.9/20 P/E 68× · PEG 1.11 100% evidence | 17.5/20 RS sector 4.5% · RS bench 18.9% · 1Y 2.8%12 of 12 weeks ahead 100% evidence |
| Exact sum: 11.8 + 15.2 + 10.9 + 17.5 = 55.4 · Decision use: Price leads the evidence: RS versus the benchmark is 18.9%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 9Yatharth Hospital & Trauma Care Services LtdYATHARTH | 54.9/100Mixed-positive evidence82% evidence | TURNING | 18.0/35 Revenue 43.9% · PAT 22.5% · OPM change -2 pp 95% evidence | 11.9/25 ROCE 12.4% · OPM 23% 76% evidence | 7.7/20 P/E 51.4× · PEG — 50% evidence | 17.3/20 RS sector 12.3% · RS bench 27.6% · 1Y 23.7%8 of 12 weeks ahead 100% evidence |
| Exact sum: 18 + 11.9 + 7.7 + 17.3 = 54.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Indraprastha Medical Corporation LtdINDRAMEDCO | 52.6/100Mixed-positive evidence94% evidence | ASLEEP | 12.7/35 Revenue 10.9% · PAT 12.6% · OPM change 0 pp 100% evidence | 18.5/25 ROCE 35.8% · OPM 20% 100% evidence | 16.9/20 P/E 17.3× · PEG 0.92 100% evidence | 4.5/20 RS sector -8.4% · RS bench -15.5% · 1Y -26.4%0 of 10 weeks ahead 70% evidence |
| Exact sum: 12.7 + 18.5 + 16.9 + 4.5 = 52.6 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 11GPT Healthcare LtdGPTHEALTH | 51.9/100Mixed-positive evidence74% evidence | BREAKING OUT | 14.4/35 Revenue 18% · PAT 0% · OPM change 3 pp 95% evidence | 19.1/25 ROCE 19.9% · OPM 19% 95% evidence | 11.2/20 P/E 27.7× · PEG — 15% evidence | 7.2/20 RS sector -15.8% · RS bench 13.2% · 1Y 3.6%7 of 10 weeks ahead 70% evidence |
| Exact sum: 14.4 + 19.1 + 11.2 + 7.2 = 51.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12Max Healthcare Institute LtdMAXHEALTH | 51.3/100Mixed-positive evidence94% evidence | TURNING | 21.2/35 Revenue 16% · PAT 26.9% · OPM change -1 pp 100% evidence | 14.5/25 ROCE 14.7% · OPM 25% 100% evidence | 9.7/20 P/E 67.5× · PEG 2.35 100% evidence | 5.9/20 RS sector -7.9% · RS bench -0.8% · 1Y -11.3%2 of 10 weeks ahead 70% evidence |
| Exact sum: 21.2 + 14.5 + 9.7 + 5.9 = 51.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Fortis Healthcare LtdFORTIS | 43.1/100Mixed-negative evidence82% evidence | ASLEEP | 19.6/35 Revenue 17.5% · PAT 18.6% · OPM change -2 pp 95% evidence | 12.6/25 ROCE 13.4% · OPM 21% 76% evidence | 9.2/20 P/E 62.8× · PEG — 50% evidence | 1.7/20 RS sector -15.1% · RS bench -3% · 1Y -6.3%4 of 12 weeks ahead 100% evidence |
| Exact sum: 19.6 + 12.6 + 9.2 + 1.7 = 43.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Narayana Hrudayalaya LtdNH | 38.3/100Mixed-negative evidence87% evidence | ASLEEP | 11.9/35 Revenue 59.6% · PAT 3.8% · OPM change -5 pp 100% evidence | 11.9/25 ROCE 15.5% · OPM 17% 100% evidence | 6.4/20 P/E 44.3× · PEG 3 65% evidence | 8.1/20 RS sector -4.3% · RS bench 2.8% · 1Y 4.7%4 of 10 weeks ahead 70% evidence |
| Exact sum: 11.9 + 11.9 + 6.4 + 8.1 = 38.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Healthcare Global Enterprises LtdHCG | 35.5/100Mixed-negative evidence75% evidence | LEADER | 10.7/35 Revenue 13.7% · PAT -21.4% · OPM change 0 pp 95% evidence | 6.5/25 ROCE 8.3% · OPM 18% 76% evidence | 8.5/20 P/E 215× · PEG — 15% evidence | 9.8/20 RS sector -4.4% · RS bench 9.1% · 1Y 1.1%11 of 12 weeks ahead 100% evidence |
| Exact sum: 10.7 + 6.5 + 8.5 + 9.8 = 35.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16Aster DM Quality Care Ltdthis pageASTERDM | 34.3/100Adverse evidence100% evidence | FADING | 15.7/35 Revenue 15.7% · PAT 3.7% · OPM change 1 pp 100% evidence | 9.0/25 ROCE 11.6% · OPM 20% 100% evidence | 1.2/20 P/E 184× · PEG 3.07 100% evidence | 8.4/20 RS sector -2.6% · RS bench 10.7% · 1Y 19.2%7 of 12 weeks ahead 100% evidence |
| Exact sum: 15.7 + 9 + 1.2 + 8.4 = 34.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Shalby LtdSHALBY | 32.6/100Adverse evidence74% evidence | ASLEEP | 16.5/35 Revenue 6.3% · PAT 100% · OPM change -1 pp 95% evidence | 2.3/25 ROCE 6.1% · OPM 13% 95% evidence | 10.8/20 P/E 39.8× · PEG — 15% evidence | 3.0/20 RS sector -28.4% · RS bench -18.7% · 1Y -34%1 of 10 weeks ahead 70% evidence |
| Exact sum: 16.5 + 2.3 + 10.8 + 3 = 32.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Krishna Institute of Medical Sciences LtdKIMS | 31.5/100Adverse evidence82% evidence | ASLEEP | 9.7/35 Revenue 30.9% · PAT -52% · OPM change -3 pp 95% evidence | 9.0/25 ROCE 9.5% · OPM 19% 76% evidence | 5.5/20 P/E 155× · PEG — 50% evidence | 7.3/20 RS sector -4% · RS bench 9.2% · 1Y 3.5%7 of 12 weeks ahead 100% evidence |
| Exact sum: 9.7 + 9 + 5.5 + 7.3 = 31.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19Jupiter Life Line Hospitals LtdJLHL | 30.2/100Adverse evidence100% evidence | BREAKING OUT | 7.1/35 Revenue 14.7% · PAT -3.1% · OPM change -3 pp 100% evidence | 10.6/25 ROCE 14.8% · OPM 19% 100% evidence | 6.6/20 P/E 47.9× · PEG 3.44 100% evidence | 5.9/20 RS sector -11.2% · RS bench 1.3% · 1Y -2.2%11 of 12 weeks ahead 100% evidence |
| Exact sum: 7.1 + 10.6 + 6.6 + 5.9 = 30.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Aster DM Quality Care Ltd's share price today?
Aster DM Quality Care Ltd trades at ₹763, +20.7% over the past year. The company is valued at ₹66,513 Cr. The stock sits at 66% of its 52-week range of ₹555–₹870, +5.8% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 27 weeks in. — as of 11 September 2026.
What were Aster DM Quality Care Ltd's latest quarterly results?
Aster DM Quality Care Ltd reported revenue of ₹1,311 Cr and net profit of ₹29.0 Cr for the Jun 26 quarter. Revenue rose 21.6% and profit fell 69.1% year on year. Earnings per share were ₹0.31. The operating margin was 20.0%, 1.0 pp higher than a year earlier. — as of 11 September 2026.
What is Aster DM Quality Care Ltd's revenue?
Aster DM Quality Care Ltd reported revenue of ₹1,311 Cr in the Jun 26 quarter, +21.6% year on year. For the full FY26 fiscal year, revenue was ₹4,643 Cr (+12.2%). Over the last 10 years revenue compounded at −1.2% a year. — as of 11 September 2026.
What is Aster DM Quality Care Ltd's profit?
Aster DM Quality Care Ltd earned ₹29.0 Cr of net profit in the Jun 26 quarter, −69.1% year on year. Full-year FY26 profit was ₹427 Cr. The operating margin ran 20.0% in the latest quarter. — as of 11 September 2026.
What is Aster DM Quality Care Ltd's market cap?
Aster DM Quality Care Ltd's market capitalisation is ₹66,513 Cr at a share price of ₹763. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 11 September 2026.
What is Aster DM Quality Care Ltd's P/E ratio?
Aster DM Quality Care Ltd trades at a P/E of 184.0×, at the most expensive it has been in 8 years, against a long-run median of 41.2×. This is a comparison with the stock's own history, not a value call — as of 11 September 2026.
Does Aster DM Quality Care Ltd pay a dividend?
Yes — Aster DM Quality Care Ltd's dividend payout was 40% of profit in FY26, and it recorded a payout in 4 of its last 13 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 11 September 2026.
Is Aster DM Quality Care Ltd overvalued?
On its own history, Aster DM Quality Care Ltd looks expensive: its P/E of 184.0× sits at the most expensive it has been in 8 years (long-run median 41.2×). That is a percentile read against the stock's own past, not a price opinion or a direction call. One caveat: margins are the best this company has ever printed — cheap on record margins is not the same thing as cheap. — as of 11 September 2026.
Is Aster DM Quality Care Ltd growing?
Yes — Aster DM Quality Care Ltd is growing: latest-quarter revenue +21.6% year on year, profit −69.1%, and the margin +1.0 pp at 20.0%. The 10-year compound rates are −1.2% (revenue) and 48.8% (profit). The earnings engine currently reads: improving — as of 11 September 2026.
How is Aster DM Quality Care Ltd performing?
Aster DM Quality Care Ltd is in a confirmed uptrend, 27 weeks in. Its latest quarter's revenue rose 21.6% and profit fell 69.1% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 1 week. This describes what the data did, not a rating. — as of 11 September 2026.
What stage is Aster DM Quality Care Ltd in?
Improving — profit growth bottomed 3 quarters ago at −93.3% and has held its recovery at +3.7%, ROCE holding at 10.8%. The read comes from the last 12 quarters of growth (revenue growth +15.7% latest, profit growth +3.7% latest, eps growth −2.5% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 11 September 2026.
Is Aster DM Quality Care Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 27 of stage 2), trading +5.8% versus its 200-day average and at 66% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 11 September 2026.
Is Aster DM Quality Care Ltd beating the market?
On recent form, yes — Aster DM Quality Care Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 1 straight week, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 8.5 years the stock moved +342% against the NIFTY 500's +156% — ahead of the index over the full window. — as of 11 September 2026.
Will Aster DM Quality Care Ltd's share price go up?
This page publishes no price forecast for Aster DM Quality Care Ltd. What it measures instead: the share price is ₹763, the price is in a confirmed uptrend 27 weeks in. Its P/E of 184.0× sits at the 100th percentile of its own 8-year range. — as of 11 September 2026.
Who owns Aster DM Quality Care Ltd?
Promoters hold 53.7% of Aster DM Quality Care Ltd, foreign institutions 10.3%, domestic institutions 16.5% and the public 19.5% (latest quarter). The biggest move on the register over the last two years: Foreign institutions cut 13.5 points over 8 quarters. — as of 11 September 2026.
Does Aster DM Quality Care Ltd have too much debt?
It is moderate — Aster DM Quality Care Ltd's debt-to-equity is 0.62, and operating profit covers the interest bill 7×. FY26 borrowings were ₹2,594 Cr against equity of ₹4,201 Cr. Read the returns on this page with that leverage in mind — as of 11 September 2026.
What is Aster DM Quality Care Ltd's capex?
Aster DM Quality Care Ltd spent ₹−3,936 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹713 Cr, with ₹420 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 11 September 2026.
What is Aster DM Quality Care Ltd's cash flow?
Aster DM Quality Care Ltd generated ₹656 Cr of operating cash flow in FY26 and ₹−57.0 Cr of free cash flow after ₹713 Cr of capital spending. Reported profit that year was ₹427 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 11 September 2026.
Is Aster DM Quality Care Ltd's profit real cash?
Not fully — over the last 3 fiscal years, 20% of Aster DM Quality Care Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹656 Cr against reported profit of ₹427 Cr. The cash then goes into a mix of the working-capital cycle and capacity. Cash-flow resolution is annual — as of 11 September 2026.
Where is Aster DM Quality Care Ltd in its business cycle?
Aster DM Quality Care Ltd's FY26 operating margin was 19.0%, against a 13-year band of 6.0%–19.0%: the top of the band — a record year. Record profitability is late-cycle territory: every ratio flatters at the top, and the story leans on margins holding. The latest quarter ran 20.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 11 September 2026.
What could break the Aster DM Quality Care Ltd story?
The sharpest disagreement: profits are rising, but only 20% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 11 September 2026.
Is Aster DM Quality Care Ltd a stock worth studying right now?
This is not investment advice. The machine read: Aster DM Quality Care Ltd's price has outrun its earnings. +20.7% in a year against EPS −93.0% — the market is paying now for delivery later. The sharpest open question: whether the cash starts following the profit. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 11 September 2026.
Not SEBI Registered !! Not Investment advice !!